Utilization of iPSC Technologies for Drug-Induced Risk and Drug Efficacy Evaluation During Drug Development

Author(s): Norimasa Miyamoto

Journal Name: Current Pharmaceutical Biotechnology

Volume 21 , Issue 9 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Blinova, K.; Dang, Q.; Millard, D.; Smith, G.; Pierson, J.; Guo, L.; Brock, M.; Lu, H.R.; Kraushaar, U.; Zeng, H.; Shi, H.; Zhang, X.; Sawada, K.; Osada, T.; Kanda, Y.; Sekino, Y.; Pang, L.; Feaster, T.K.; Kettenhofen, R.; Stockbridge, N.; Strauss, D.G.; Gintant, G. International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Rep., 2018, 24(13), 3582-3592.
[2]
Strauss, D.G.; Gintant, G. Li, Z3, Wu W.; Blinova, K.; Vicente, J.; Turner, J.R.; Sager, P.T. Comprehensive In Vitro Proarrhythmia Assay (CiPA) update from a cardiac safety research consortium / Health and Environmental Sciences Institute / FDA meeting. Ther. Innov. Regul. Sci., 2018, 53(4), 519-525.
[3]
Millard, D.; Dang, Q.; Shi, H.; Zhang, X.; Strock, C.; Kraushaar, U.; Zeng, H.; Levesque, P.; Lu, H.R.; Guillon, J.M.; Wu, J.C.; Li, Y.; Luerman, G.; Anson, B.; Guo, L.; Clements, M.; Abassi, Y.A.; Ross, J.; Pierson, J.; Gintant, G. Cross-site reliability of human induced pluripotent stem cell-derived cardiomyocyte based safety assays using microelectrode arrays: Results from a blinded CiPA pilot study. Toxicol. Sci., 2018, 164(2), 550-562.
[4]
Bot, C.T.; Juhasz, K.; Haeusermann, F.; Polonchuk, L.; Traebert, M.; Stoelzle-Feix, S. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes. J. Pharmacol. Toxicol. Methods, 2018, 93, 46-58.
[5]
Blinova, K.; Stohlman, J.; Vicente, J.; Chan, D.; Johannesen, L.; Hortigon-Vinagre, M.P.; Zamora, V.; Smith, G.; Crumb, W.J.; Pang, L.; Lyn-Cook, B.; Ross, J.; Brock, M.; Chvatal, S.; Millard, D.; Galeotti, L.; Stockbridge, N.; Strauss, D.G. Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias. Toxicol. Sci., 2017, 155(1), 234-247.
[6]
Gintant, G.; Sager, P.T.; Stockbridge, N. Evolution of strategies to improve preclinical cardiac safety testing. Nat. Rev. Drug Discov., 2016, 15(7), 457-471.
[7]
Colatsky, T.; Fermini, B.; Gintant, G.; Pierson, J.; Sager, P.; Sekino, Y.; Strauss, D.; Stockbridge, N. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative - update on progress. J. Pharmacol. Toxicol. Methods, 2016, 81, 15-20.
[8]
Fermini, B.; Hancox, J.C.; Abi-Gerges, N.; Bridgland-Taylor, M.; Chaudhary, K.W.; Colatsky, T.; Correll, K.; Crumb, W.; Damiano, B.; Erdemli, G.; Gintant, G.; Imredy, J.; Koerner, J.; Kramer, J.; Levesque, P.; Li, Z.; Lindqvist, A.; Obejero-Paz, C.A.; Rampe, D.; Sawada, K.; Strauss, D.G.; Vandenberg, J.I. A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J. Biomol. Screen., 2015, 21(1), 1-11.
[9]
Sager, P.T.; Gintant, G.; Turner, J.R.; Pettit, S.; Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am. Heart J., 2014, 167(3), 292-300.
[10]
Ando, H.; Yoshinaga, T.; Yamamoto, W.; Asakura, K.; Uda, T.; Taniguchi, T.; Ojima, A.; Shinkyo, R.; Kikuchi, K.; Osada, T.; Hayashi, S.; Kasai, C.; Miyamoto, N.; Tashibu, H.; Yamazaki, D.; Sugiyama, A.; Kanda, Y.; Sawada, K.; Sekino, Y. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods, 2017, 84, 111-127.
[11]
Yamamoto, W.; Asakura, K.; Ando, H.; Taniguchi, T.; Ojima, A.; Uda, T.; Osada, T.; Hayashi, S.; Kasai, C.; Miyamoto, N.; Tashibu, H.; Yoshinaga, T.; Yamazaki, D.; Sugiyama, A.; Kanda, Y.; Sawada, K.; Sekino, Y. Electrophysiological characteristics of human iPSC-derived cardiomyocytes for the assessment of drug-induced proarrhythmic potential. PLoS One, 2016, 11(12) e0167348
[12]
Yamazaki, D.; Kitaguchi, T.; Ishimura, M.; Taniguchi, T.; Yamanishi, A.; Saji, D.; Takahashi, E.; Oguchi, M.; Moriyama, Y.; Maeda, S.; Miyamoto, K.; Morimura, K.; Ohnaka, H.; Tashibu, H.; Sekino, Y.; Miyamoto, N.; Kanda, Y. Usefulness of human induced stem cell-derived cardiomyocytes for proarrhythmia risk prediction using 2-dimensional categorization system. J. Pharmacol. Sci., 2018, 136(4), 249-256.
[13]
Nozaki, Y.; Honda, Y.; Watanabe, H.; Saiki, S.; Koyabu, K.; Itoh, T.; Nagasawa, C.; Nakamori, C.; Nakayama, C.; Iwasaki, H.; Suzuki, S.; Tanaka, K.; Takahashi, E.; Miyamoto, K.; Morimura, A.; Yamanishi, A.; Endo, H.; Shinozaki, J.; Nogawa, H.; Shinozawa, T.; Saito, F.; Kunimatsu, T. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul. Toxicol. Pharmacol., 2017, 88, 238-251.
[14]
Kitaguchi, T. Moriyam,a Y.; Taniguchi, T.; Maeda, S.; Ando, H.; Uda, T.; Otabe, K.; Oguchi, M.; Shimizu, S.; Saito, H.; Toratani, A.; Asayama, M.; Yamamoto, W.; Matsumoto, E.; Saji, D.; Ohnaka, H.; Miyamoto, N. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods, 2017, 85, 73-81.
[15]
Takasuna, K.; Asakura, K.; Araki, S.; Ando, H.; Kazusa, K.; Kitaguchi, T.; Kunimatsu, T.; Suzuki, S.; Miyamoto, N. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative. J. Pharmacol. Toxicol. Methods, 2017, 83, 42-54.
[16]
Araki, T.; Iwazaki, N.; Ishiguro, N.; Sakamoto, A.; Nagata, K.; Ohbuchi, M.; Moriguchi, H.; Motoi, M.; Shinkyo, R.; Homma, T.; Sakamoto, S.; Iwase, Y.; Ise, R.; Nakanishi, Y.; Uto, M.; Inoue, T. Requirements for human iPS cell-derived hepatocytes as an alternative to primary human hepatocytes for assessing absorption, distribution, metabolism, excretion and toxicity of pharmaceuticals. Fundam. Toxicol. Sci, 2016, 3(3), 89-99.
[17]
Nozaki, Y.; Honda, Y.; Watanabe, H.; Saiki, S.; Koyabu, K.; Itoh, T.; Nagasawa, C.; Nakamori, C.; Nakayama, C.; Iwasaki, H.; Suzuki, S.; Washio, I.; Takahashi, E.; Miyamoto, K.; Yamanishi, A.; Endo, H.; Shinozaki, J.; Nogawa, H.; Kunimatsu, T. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol., 2016, 77, 75-86.
[18]
Kitaguchi, T.; Moriyama, Y.; Taniguchi, T.; Ojima, A.; Ando, H.; Uda, T.; Otabe, K.; Oguchi, M.; Shimizu, S.; Saito, H.; Morita, M.; Toratani, A.; Asayama, M.; Yamamoto, W.; Matsumoto, E.; Saji, D.; Ohnaka, H.; Tanaka, K.; Washio, I.; Miyamoto, N. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities. J. Pharmacol. Toxicol. Methods, 2016, 78, 93-102.
[19]
Asakura, K.; Hayashi, S.; Ojima, A.; Taniguchi, T.; Miyamoto, N.; Nakamori, C.; Nagasawa, C.; Kitamura, T.; Osada, T.; Honda, Y.; Kasai, C.; Ando, H.; Kanda, Y.; Sekino, Y.; Sawada, K. Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyo. J. Pharmacol. Toxocol. Methods, 2015, 75, 17-26.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 9
Year: 2020
Page: [750 - 751]
Pages: 2
DOI: 10.2174/138920102109200610123205

Article Metrics

PDF: 52
HTML: 5